Trichoderma Allergy: Biocontrol Agent, Enzyme Worker Sensitizer, No Shots
Trichoderma is industrially famous as the source of cellulases used in biofuel, detergent, and textile production, and agriculturally significant as a biological fungicide. Occupationally, it sensitizes enzyme-production workers via IgE-binding cellulases (~50–60 kDa). As an indoor mold, it is a water-damage co-indicator found alongside Stachybotrys and Chaetomium. No WHO/IUIS allergen has been formally characterized, no SCIT extract is commercially available, and no controlled SCIT trial exists.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Trichodermais covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Trichoderma Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to trichoderma — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of trichoderma allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of trichoderma immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of trichoderma extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for trichoderma allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing trichoderma extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription trichoderma immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat trichoderma allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Trichoderma?
The biology, taxonomy, and clinical fingerprint of Trichoderma — the foundation of how SCIT targets it.
Trichoderma harzianum — fast-growing green-spored colony. Industrially produced as biocontrol agent against plant-pathogenic fungi; T. reesei produces the cellulases used in biofuel and detergent production.
- Scientific name
- Trichoderma viride / Trichoderma longibrachiatum / Trichoderma harzianum
- Family
- HypocreaceaeHypocreales, Sordariomycetes, Ascomycota — same order as Fusarium and Stachybotrys
- Type
- Occupational and indoor water-damage mold — perennial, primarily occupational allergy risk
- Native to
- Cosmopolitan; ubiquitous in soil; used industrially as biocontrol agent and enzyme source
- Allergen proteins
- No WHO/IUIS-recognized Trichoderma allergens to date (verified allergen.org 2025)IgE-binding cellulases ~50–60 kDa identified in research panels for T. reesei (Doekes G et al., Clin Exp Allergy 1999)Cellulases are the primary occupational sensitization proteins — no designated IUIS names
- Particle size
- Conidia small 3–5 µm — respirable with alveolar penetration in occupational exposure
- Avoidance difficulty
- Manageable
How Trichoderma Allergy Presents
Symptoms by body system — useful for distinguishing Trichoderma sensitivity from overlapping allergies and infections.
Respiratory
- Occupational asthma in enzyme-production workers, bakers, and biocontrol applicators with Trichoderma cellulase exposure (Vanhanen M et al., Allergy 2000)
- Rhinitis and cough in occupationally exposed enzyme-industry workers
- Allergic rhinitis in patients with water-damaged building Trichoderma exposure
- Rare invasive pulmonary disease in severely immunocompromised patients (T. longibrachiatum) — not IgE-mediated
Ocular
- Allergic conjunctivitis in occupationally sensitized enzyme workers during cellulase exposure
- Eye irritation from Trichoderma spores or cellulase aerosols in production environments
- Periorbital edema during acute occupational allergen exposure in sensitized individuals
Dermal
- Occupational contact dermatitis from cellulase enzyme preparations in enzyme-industry and textile workers
- Contact urticaria in biocontrol agricultural applicators with Trichoderma product exposure
- Skin prick test reactivity with T. viride extract in occupationally sensitized individuals
Systemic
- Invasive Trichoderma infection (T. longibrachiatum) in severely immunocompromised patients: HSCT recipients, leukemia — not IgE-mediated (Kratzer C et al., Med Mycol 2006)
- Occupational asthma progression to chronic airway obstruction if unaddressed in enzyme-industry workers
- Fatigue and systemic symptoms in chronically exposed enzyme-production workers with inadequate ventilation
A positive Trichoderma IgE in an enzyme-industry worker is fundamentally an occupational medicine problem — the answer is engineering controls and respiratory surveillance, not shots. My role is to confirm the sensitization, document the occupational exposure, and refer to occupational health for workplace intervention. If they also have home water-damage exposure, we address that with remediation. SCIT for Trichoderma is not something I can prescribe.
Where Trichoderma Triggers Year-Round
Trichoderma is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundYear-round in occupational and indoor building settings; slightly elevated in warmer months for agricultural biocontrol applications· Perennial occupational exposure; agricultural biocontrol application peak in growing season (April–September)
US Exposure Map
0 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Trichoderma Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Trichoderma cross-reactivity is assessed only at the extract level due to absent WHO/IUIS allergen characterization; serine-protease and cellulase enzyme families shared with other Hypocreales molds represent the primary cross-reactivity basis.
Same Hypocreales order; serine-protease and cellulase enzyme overlap; both agricultural molds with extract-level cross-reactivity in mold-mix panels
Same Hypocreales order; co-occurring water-damage context; limited characterized component overlap
Co-occurring water-damage Sordariomycetes; both produce chitinases and cellulases; shared building-remediation context
Is SCIT Right for Your Trichoderma Allergy?
This five-question assessment helps identify whether your Trichoderma exposure is primarily occupational or building-related — because the recommended interventions are quite different.
Do you work in enzyme production, textile manufacturing, paper mills, or agricultural biocontrol application?
The Trichoderma SCIT Protocol
Trichoderma SCIT is essentially never prescribed. No FDA-standardized extract exists, no WHO/IUIS allergen has been characterized, and no DBPC-RCT has been conducted. Occupational exposure reduction is the primary evidence-based intervention.
Engineering controls for enzyme-industry workers include enclosed production processes with HEPA-filtered air handling, process isolation for high-dust operations, local exhaust ventilation, and elimination of open-process cellulase handling. Personal protective equipment: N95 respirators at minimum, full-face respirators during high-exposure tasks. Medical surveillance: annual spirometry and symptom questionnaire for all exposed workers. Occupational hygiene monitoring of airborne enzyme dust concentrations. Early case identification and job reassignment for sensitized workers to prevent disease progression to chronic obstructive pattern.
Trichoderma co-occurring with Stachybotrys and Chaetomium in water-damaged buildings requires standard moisture-source control and professional remediation. HEPA filtration, humidity control below 50%, and removal of contaminated porous materials. No special Trichoderma-specific protocol beyond standard EPA mold remediation guidelines.
SCIT for Trichoderma is not prescribed. If allergy testing reveals co-positive evidence-supported molds (Alternaria foremost), immunotherapy for those co-positive allergens can be discussed with a board-certified allergist.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Trichoderma SCIT
No controlled SCIT trial exists for Trichoderma. The relevant efficacy data for Trichoderma-related disease management is occupational engineering controls and monitoring — not immunotherapy.
- Occupational asthma prevention with engineering controls (enzyme-industry reference)70%Vanhanen M et al., Allergy 2000 — enzyme-industry occupational asthma significantly reduced by workplace engineering controls and surveillance programs
- Alternaria SCIT combined score reduction at year 3 (co-positive mold with RCT evidence)64%Kuna P et al., JACI 2011 — Alternaria as the practical immunotherapy target for co-positive patients
No DBPC-RCT has been attempted for Trichoderma SCIT. The AAAAI/ACAAI Practice Parameter does not include Trichoderma in the recommended mold-immunotherapy panel. For occupationally sensitized enzyme workers, engineering controls and medical surveillance have the best evidence. For building occupants with water-damage exposure, moisture remediation is primary. SCIT for co-positive evidence-supported molds (Alternaria foremost) is the practical immunotherapy path when mold sensitization warrants treatment.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Trichoderma SCIT Side Effects
Trichoderma SCIT is not prescribed. The safety considerations concern occupational cellulase aerosol exposure and building remediation exposure rather than injection reactions.
Local reactions
1 documented| Reaction | Rate | Severity |
|---|---|---|
Occupational sensitization — initial IgE response to cellulase aerosol in enzyme workers Sensitization can progress to occupational asthma if engineering controls are not implemented; once sensitized, very low aerosol concentrations can trigger symptoms | Rate Documented in unprotected enzyme workers — Vanhanen 2000 | Moderate |
Systemic reactions
2 documented| Reaction | Rate | Severity |
|---|---|---|
Occupational asthma progression in unprotected sensitized workers Occupational asthma from enzyme exposure can progress to chronic obstruction if continued high-dose exposure persists after sensitization | Rate Significant risk without controls after sensitization | Moderate |
Invasive Trichoderma infection (T. longibrachiatum) in severely immunocompromised patients Not IgE-mediated; antifungal treatment is the management — separate from allergy | Rate Rare — documented in HSCT and leukemia patients | Severe |
The primary safety concern for Trichoderma is occupational sensitization leading to progressive airway disease in unprotected enzyme workers. Once sensitized, extremely low aerosol concentrations can trigger reactions — making job reassignment necessary in some cases. This is not an injection-safety concern but a workplace-health concern.
SCIT vs Alternatives for Trichoderma
For Trichoderma-related allergy, the evidence-based management hierarchy is occupational controls first, building remediation second, pharmacotherapy third, and SCIT for co-positive evidence-supported molds — not Trichoderma-specific SCIT, which does not exist.
| Criterion | Trichoderma SCIT | Engineering ControlsBest | At-Home Alternaria SCIT (Curex, if co-positive) | Medications |
|---|---|---|---|---|
| Effectiveness | DOES NOT EXIST | ~70% occupational asthma prevention with full implementation (Vanhanen 2000) | 63.5% combined score reduction (Kuna 2011) | Symptom control only |
| 5-yr cost | N/A | Employer-borne engineering cost; no patient cost | $3,500–$15,000 over 5 years | $500–$2,000/year |
| Duration | N/A | Ongoing — part of occupational safety | 3–5 years | Indefinite |
| Convenience | N/A | Workplace program — no clinic visits | At-home self-injection; weekly then monthly | Daily pills and inhalers |
| Safety | N/A | No injection risk | Virtual Shot Room–supervised dosing + prescribed epi on hand | Generally safe |
| Lasting effect | Unknown | Sustained with continued controls | 7–12+ years post-treatment | No disease modification |
Trichoderma SCIT
Engineering ControlsBest
At-Home Alternaria SCIT (Curex, if co-positive)
Medications
Occupational engineering controls are the most evidence-supported intervention for enzyme-industry Trichoderma sensitization. For patients also sensitized to Alternaria or other evidence-supported molds, Curex delivers immunotherapy as an at-home allergy shot with pricing confirmed in a current program quote: a serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation — though Trichoderma-specific immunotherapy data does not exist.
What Trichoderma SCIT Actually Costs
Occupational asthma from Trichoderma cellulase exposure may qualify for workers' compensation coverage under applicable state laws. Standard allergy testing for co-positive molds with SCIT evidence is covered by most major insurers under laboratory benefits. Trichoderma-specific SCIT is not a billable insurance claim. Curex at-home IgE testing identifies specific trichoderma sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your trichoderma allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Trichoderma SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Trichoderma is a fast-growing green-spored fungus found ubiquitously in soil worldwide. Several species — particularly T. harzianum and T. viride — are used commercially as biological fungicides because they parasitize and outcompete plant-pathogenic fungi including Fusarium, Rhizoctonia, and Botrytis on crop plants. This biocontrol activity is achieved through mycoparasitism (Trichoderma physically attacks and destroys other fungi), enzyme production (cellulases and glucanases that break down fungal cell walls), and competition for nutrients and space. Agricultural workers who apply Trichoderma-based biopesticides are at occupational exposure risk, particularly those mixing and spraying large quantities of concentrated spore suspensions without adequate respiratory protection. Trichoderma is also extensively used in biocontrol of plant diseases in horticulture, viticulture, and large-scale crop production.
Trichoderma reesei (also known as Hypocrea jecorina) is the dominant industrial source of cellulase and hemicellulase enzymes used in the biofuel, textile, paper, animal feed, and detergent industries. Named after the US Army researcher Elwyn Reese who first described it from deteriorating military canvas during World War II, T. reesei is among the most prolific cellulase producers in nature — secreting large quantities of enzyme proteins into its growth medium. Industrial enzyme production involves large-scale fermentation of T. reesei, followed by downstream processing that generates cellulase aerosols. Workers in these facilities can develop IgE sensitization to the cellulase proteins (approximately 50–60 kDa). Vanhanen M et al. (Allergy 2000) documented occupational asthma in enzyme-industry workers from Trichoderma-derived cellulase exposure. Engineering controls including enclosed processing, HEPA ventilation, and respiratory protection programs are the evidence-supported prevention measures.
Yes, but very rarely — and almost exclusively in severely immunocompromised patients. Trichoderma longibrachiatum has been documented as a rare cause of invasive disease including peritonitis, lung disease, and meningoencephalitis in patients with hematopoietic stem-cell transplantation (HSCT), leukemia, or severe combined immunodeficiency. Kratzer C et al. (Med Mycol 2006) reviewed cases of invasive T. longibrachiatum disease in immunocompromised hosts. These infections carry high mortality and are difficult to treat because Trichoderma shows variable susceptibility to antifungals — voriconazole and posaconazole are sometimes used but with unpredictable results, and immune reconstitution is critical for survival. For immunocompetent individuals with Trichoderma exposure, the concern is IgE-mediated allergy and occupational asthma — not invasive infection. Severely immunocompromised patients should avoid heavy Trichoderma-spore environments (agricultural biocontrol application, enzyme-production facilities) and should discuss exposure risk with their infectious-disease specialist.
Yes — agricultural workers have multiple Trichoderma exposure routes. Direct application of Trichoderma-based biocontrol products during crop treatment is the highest-risk scenario for sensitization. Soil-disturbing activities (plowing, harvesting, transplanting) release naturally occurring Trichoderma spores from soil, though at lower concentrations than direct product application. Greenhouse workers mixing and applying T. harzianum or T. viride concentrates without respiratory protection are among the most highly exposed groups. The AAAAI/ACAAI Practice Parameter recognizes occupational allergen exposure as a distinct clinical category requiring exposure assessment as part of allergy management. For agricultural workers with occupational Trichoderma sensitization, the intervention is workplace controls, appropriate PPE (N95 masks during product application), and medical surveillance — not SCIT.
Yes — Trichoderma is recovered from water-damaged drywall, wallpaper, gypsum board, and wood in buildings with significant moisture problems. It co-occurs with Stachybotrys and Chaetomium as an indicator of chronic moisture damage. Trichoderma prefers cellulose-rich substrates and high humidity, similar to the other water-damage indicator molds. Home exposure levels are generally much lower than occupational enzyme-production exposures, and the clinical significance of home Trichoderma sensitization is not well quantified. If symptoms developed or worsened after known water damage and standard mold panels are negative, an extended panel with Trichoderma may be considered by a specialist — though ImmunoCAP for Trichoderma is not widely commercially available. The primary home management action is the same as for all water-damage molds: fix the moisture source, remediate with professional help if area exceeds 10 square feet, and maintain indoor humidity below 50%.
Theoretically, yes — if researchers characterize and sequence the major Trichoderma IgE-binding cellulases, assign them WHO/IUIS names, produce recombinant or standardized extract formulations, and conduct controlled clinical trials. The precedent exists: Alternaria SCIT went through exactly this process — Alt a 1 was characterized, standardized European extracts were produced, and DBPC-RCTs demonstrated efficacy. For Trichoderma, the current barrier is the absence of WHO/IUIS-named allergens. The IgE-binding cellulases (approximately 50–60 kDa) from T. reesei have been identified in research panels (Doekes G et al., Clin Exp Allergy 1999), but have not progressed to standardized clinical allergen products. Given that Trichoderma occupational asthma affects a relatively small population compared to Alternaria allergy (which affects 13% of the US general population), commercial development of Trichoderma SCIT extracts is not currently a priority for major allergen manufacturers. No timeline exists for this development.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.